Pharmaceutical Outsourcing covers news of importance to the contract services segment of the pharmaceutical industry.
Collected from the most trusted on-line resources, these news stories are chosen and published here based on their relevance to the pharmaceutical industry.
Topics of interest typically include: mergers and acquisitions, service additions, new capabilities, personnel changes, news from the FDA and other international regulatory and standard-setting agencies, and new outsourcing contracts and deals.
If you are looking to stay up-to-date with the news in your industry, this resource is vital for your industry knowledge.
Societal CDMO, Inc. has entered into a three-year manufacturing and supply agreement with InfectoPharm for Ritalin LA® capsules (methylphenidate hydrochloride extended-release capsules) in Europe.
read more
Societal CDMO, Inc. has been selected by AmyriAD Pharma to provide CDMO services to support the ongoing clinical development of AD101. The compound, a novel T-type calcium channel modulator, is currently in clinical development for the treatment of ...
read more
Wednesday, April 27, 2022
Societal CDMO, Inc. has been awarded a new manufacturing and packaging task order agreement by the National Cancer Institute’s Division of Cancer Treatment and Diagnosis (DCTD). The new contract is an individual task order of more than $400,000 for ...
read more
Societal CDMO, Inc. has signed an amendment to its license and supply agreement with Lannett Company for the marketing of Verapamil PM and Verelan SR. Under terms of the amendment, Societal will now receive improved overall economics, including a 10%...
read more
Societal CDMO, Inc. announced a key new customer project utilizing its automated fill/finish line and lyophilization unit at the company’s San Diego facility.
read more
Thursday, September 24, 2020
Sobrera and Recipharm have entered into an agreement for the formulation development and manufacturing of SO-001, a new oral treatment for Alcohol Use Disorder.
read more
Sobi® announced that its contract with Pfizer for the manufacture of drug substance for ReFacto AF®/Xyntha® (ReFacto) has been amended due to clarity of final order volumes and will now expire in the first quarter of 2024, earlier than the previous ...
read more
Sobi® announced a streamlining and simplification of the contractual economics for nirsevimab.
read more
Thursday, October 29, 2015
SNBL USA, Ltd. has been awarded a contract by the Biomedical Advanced Research and Development Authority (BARDA) within the Office of the Assistant Secretary for Preparedness and Response (ASPR) in the U.S. Department of Health and Human Services (...
read more
Tuesday, November 20, 2012
SNBL USA, Ltd., a wholly owned subsidiary of Shin Nippon Biomedical Laboratories, Ltd., today announced it has received a formal close out letter from the U.S. Food and Drug Administration (FDA) indicating that it has successfully resolved all the ...
read more
SNBL USA, the experts in primate research, has entered into a consulting agreement with Dr. Pritam Sahota of Global ToxPath, LLC. Sahota is a recognized industry leader in toxicologic pathology evaluations within the framework of pharmaceutical ...
read more
Wednesday, April 04, 2018
GSL Biotech and VectorBuilder have formed a partnership to create a complete cloning solution, allowing customers to order their entire custom plasmids directly from VectorBuilder through GSL Biotech’s “SnapGene” software.
read more
Monday, November 13, 2017
Synbio Technologies and GSL Biotech have finalized a non-exclusive agreement allowing customers of GSL Biotech’s “SnapGene” software to order constructs directly from Synbio Technologies.
read more
Monday, February 11, 2019
Ompi and SiO2 Medical Products (SMP) jointly announce a collaboration agreement to receive SMP's proprietary primary containers in Ompi’s industry-recognized EZ-fill packaging configurations in trays and nest & tubs.
read more
Friday, September 15, 2017
Smithers Viscient, a global CRO, has appointed Craig Draper, Ph.D. to the role of Vice President, Global Commercial Development
read more